OBGYN.net Staff

Mobile healthcare apps and devices are expected to grow at a rate of 61% a year, with 50% of healthcare professionals using at least one app. Ob/gyns are leading the charge, and these 8 apps are helping MDs and HCPs manage patients and stay current on everything happening in the field.

The risk of stillbirth in uncomplicated monochorionic twin pregnancies is severalfold higher than that for dichorionic twin pregnancies throughout the third trimester, concluded a systematic review and meta-analysis.

In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.

Exposure to pollution in early life may increase the risk of autism spectrum disorders, according to researchers at the Harvard School of Public Health.

test

Authors of a new study identified four strategies for cervical cancer screening that maximize benefits while reducing the potential for harm.

The FDA has changed the Pregnancy Category of magnesium sulfate from ‘A’ to ‘D,’ indicating that there is “positive evidence of human fetal risk” when the drug is used during pregnancy.

Both patients and physicians are confused about cord blood banking. How do you address the issue?

Women with early, surgically-induced menopause had greater incidence of neurological problems, including declining cognitive function and early indicators of Alzheimer’s disease in a study reported at the American Academy of Neurology meeting.

Diana Bianchi discusses noninvasive prenatal testing, including false positives and testing average-risk women, at ACOG's Annual Meeting.

Plan B and other levonorgestrel-based emergency contraception will be available over-the-counter without age restrictions.

Advisers to the FDA on Monday voted decisively against approving two non-hormonal medications to treat hot flashes, a common symptom of menopause.

The modern gynecologist needs to be aware of the possibility of cervical ectopic pregnancy, since interventions like dilatation and curettage performed for an incomplete abortion can be catastrophic.

Osphena (ospemifene) has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.

Between 70 and 90 percent of women carrying a fetus diagnosed in utero with Down syndrome choose to abort. Is terminating a fetus diagnosed with Down syndrome the same as terminating a fetus because of its gender?

Preconception genetic carrier testing has become more widely available and affordable, but is not always routinely recommended by physicians. Do you encourage it among patients planning to conceive?

Today, the FDA approved Oxytrol for Women, a patch containing oxybutynin that treats overactive bladder, for over-the-counter sale to women ages 18 and older.

According to the American Medical Association, the southern part of the United States is facing an HIV epidemic. Do you proactively talk with your patients about their risk of contracting HIV?

Curabitur egestas enim non sem mollis nec dictum dui venenatis. Sed ullamcorper, risus nec suscipit dictum, libero urna bibendum ligula, vitae feugiat lacus dui pharetra sapien. Nam et velit sapien. Sed sollicitudin magna at metus vehicula non suscipit justo interdum.